Weekly Recap

Remternetug Significantly Reduces Amyloid Plaque, Phase 3 INTUNE Study Accelerated, Pitolisant Approved for Pediatric Narcolepsy by EMA

ByNeurologyLive® Staff

April 8th 2023

Neurology News Network for the week ending April 8, 2023. [WATCH TIME: 4 minutes]

Lecanemab Adds Quality-Adjusted Life Years, FDA to Hold AdComm Meeting Over NurOwn, SYMBYX Neuro Improves PD Symptoms

ByNeurologyLive® Staff

April 1st 2023

Neurology News Network for the week ending April 1, 2023. [WATCH TIME: 4 minutes]

Efgartigimod Effective Across Subgroups, FDA to Hold AdComm Meeting on SRP-9001, Reboxetine Demonstrates Positive Effect on Obstructive Sleep Apnea

ByMarco Meglio

March 25th 2023

Neurology News Network for the week ending March 25, 2023. [WATCH TIME: 3 minutes]

Cognitive and Functional Differences in Parkinson, FDA Lifts Hold on IkT-148009, Solanezumab Shows No Impact on Cognitive Decline

ByNeurologyLive® Staff

March 18th 2023

Neurology News Network for the week ending March 18, 2023. [WATCH TIME: 4 minutes]

Efgartigimod Improves HR-Related Quality of Life, Traditional Approval for Lecanemab Pending, Satrlizumab Benefits NMOSD After Switching

ByNeurologyLive® Staff

March 11th 2023

Neurology News Network for the week ending March 11, 2023. [WATCH TIME: 3 minutes]

Gene Therapy ST-920 Shows Benefit in Fabry, Intermittent Calorie Restriction in Multiple Sclerosis, High Economic Burden Identified in NMOSD

ByNeurologyLive® Staff

March 4th 2023

Neurology News Network for the week ending March 4, 2023. [WATCH TIME: 3 minutes]

Sodium Oxybate Alters Sleep Structure, FDA Approves Deutetrabenazine, Associations of Stroke Decreased With Age

ByNeurologyLive® Staff

February 25th 2023

Neurology News Network for the week ending February 26, 2022. [WATCH TIME: 3 minutes]

CNM-Au8 Impacts Neuronal Structural Integrity, Mobile Stroke Units and Direct Transfer to Angiography, Cognitive Impairments Higher in RBD Before Parkinson Disease

ByNeurologyLive® Staff

February 18th 2023

Neurology News Network for the week ending February 18, 2023. [WATCH TIME: 4 minutes]

PHOENIX Study Meets Enrollment, Atogepant and Ubrogepant Safe, ABATE Trial Highlights Targeted Response of Alzheimer Vaccine

ByNeurologyLive® Staff

February 11th 2023

Neurology News Network for the week ending February 11, 2023. [WATCH TIME: 3 minutes]

New Diagnostic Criteria Established for MOGAD, FDA Approves Proclaim XR SCS System, Clinical Hold on IKT-148009 Lifted

ByNeurologyLive® Staff

February 4th 2023

Neurology News Network for the week ending February 4, 2023. [WATCH TIME: 4 minutes]

Evoke SCS System Shows Positive 36-Month Results, FDA Lifts Hold on FORTIS, Complete Response Letter Issued for Donanemab

ByNeurologyLive® Staff

January 28th 2023

Neurology News Network for the week ending January 28, 2023. [WATCH TIME: 4 minutes]

COVID-19 Vaccine and Potential Stroke Concern, Associations Between AEDs and Incident Parkinson, FDA Accepts sBLA for DaxibolinumtoxinA

ByNeurologyLive® Staff

January 21st 2023

Neurology News Network for the week ending January 21, 2022. [WATCH TIME: 3 minutes]

24-Hour Levodopa Solution Improves ON Time, Eisai Submits sBLA for Traditional Approval of Lecanemab, Rare Case of Seronegative NMOSD Identified

ByNeurologyLive® Staff

January 14th 2023

Neurology News Network for the week ending January 14, 2022. [WATCH TIME: 4 minutes]

FDA Approves Essential Tremor Treatment, Alzheimer's Association Files Request to CMS, Duchenne Therapy ENTR-601-44 Placed on Hold

ByNeurologyLive® Staff

December 31st 2022

Neurology News Network for the week ending December 31, 2022. [WATCH TIME: 3 minutes]

WVE-N531's Impact on Exon Skipping, PROs Improved With Early DMT Initiation, Carbon Dioxide Improves Insomnia Sleep

ByNeurologyLive® Staff

December 24th 2022

Neurology News Network for the week ending December 24, 2022. [WATCH TIME: 4 minutes]

Genetic Links to PML Identified, MARINA Trial Findings Announced, Educational Videos Improve CPAP Adherence

ByNeurologyLive® Staff

December 17th 2022

Neurology News Network for the week ending December 17, 2022. [WATCH TIME: 4 minutes]

Communication Critical for Dravet Syndrome, DNL343 to Enter HEALEY ALS Trial, Combination of Seizures and Dementia Leads to Worse Outcomes

ByNeurologyLive® Staff

December 10th 2022

Neurology News Network for the week ending December 10, 2022. [WATCH TIME: 4 minutes]

Donanemab Outperforms Aducanumab in Amyloid Clearance, FDA Grants Priority Review to SRP-9001, Atogepant Improves PROs

ByNeurologyLive® Staff

December 3rd 2022

Neurology News Network for the week ending December 3, 2022. [WATCH TIME: 3 minutes]

Aquatic Therapy Improves MS Fatigue, MS Disease Pathology Not Defined by Courses, Rituximab Shows Positive Effect in Myasthenia Gravis

ByNeurologyLive® Staff

November 26th 2022

Neurology News Network for the week ending November 26, 2022. [WATCH TIME: 4 minutes]

Positive Results of STK-001 in Dravet, Zavegepant Meets Primary End Points, FDA Accepts NDA of Zilucoplan for Myasthenia Gravis

ByNeurologyLive® Staff

November 19th 2022

Neurology News Network for the week ending November 19, 2022. [WATCH TIME: 3 minutes]

FDA Rejects BLA for NurOwn, Simvastatin Futile as DMT for Parkinson, Music Potentially Improves Insomnia Symptoms

ByNeurologyLive® Staff

November 12th 2022

Neurology News Network for the week ending November 12, 2022. [WATCH TIME: 4 minutes]

Poor Sleep Associated With Cannabis and Alcohol Use, Dietary Approaches in MS, Noninvasive Brain Stimulation Effective in Alzheimer

ByNeurologyLive® Staff

November 5th 2022

Neurology News Network for the week ending November 5, 2022. [WATCH TIME: 3 minutes]

Apitegromab Improves Quality of Life in SMA, ARB Therapy Leads to Lowered Epilepsy Risk, Donanemab Reduces Alzheimer-Related Plasma Biomarkers

ByMarco Meglio

October 29th 2022

Neurology News Network for the week ending October 28, 2022. [WATCH TIME: 4 minutes]

Positive Interim Report on Fosgonimeton, Lower ASPECTS Scores Impact Efficacy of EVT, FDA Extends Review of Tofersen

ByNeurologyLive® Staff

October 22nd 2022

Neurology News Network for the week ending October 22, 2022. [WATCH TIME: 4 minutes]

Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD

ByNeurologyLive® Staff

October 15th 2022

Neurology News Network for the week ending October 15, 2022. [WATCH TIME: 3 minutes]

Ublituximab Outperforms Teriflunomide on ARRs, CNM-Au8 Fails HEALEY ALS Trial, Benefits of Aerobic Exercise in Multiple Sclerosis

ByNeurologyLive® Staff

October 8th 2022

Neurology News Network for the week ending October 8, 2022. [WATCH TIME: 3 minutes]

Verdiperstat Fails ALS Study, Lecanemab Shines in Latest Phase 3 Findings, Ofatumumab Continues Superiority Over Teriflunomide

ByNeurologyLive® Staff

October 1st 2022

Neurology News Network for the week ending October 1, 2022. [WATCH TIME: 4 minutes]

Rituximab as Initial gMG Treatment, WVE-003 Proves Positive in HD, and Incidence of Guillian-Barré After COVID-19 Vaccination

ByNeurologyLive® Staff

September 24th 2022

Neurology News Network for the week ending September 24, 2022. [WATCH TIME: 4 minutes]

Abnormal Vascular Hemodynamics Linked With Tau, Constant Therapy Shows Feasibility in Alzheimer Disease, LIFT-AD Study Amended

ByNeurologyLive® Staff

September 17th 2022

Neurology News Network for the week ending September 17, 2022. [WATCH TIME: 4 minutes]

New Study on COVID-19 Vaccinations in MS, FDA Lifts Hold on SRP-5051, Implantable Loop Recorder and Atrial Fibrillation

ByNeurologyLive® Staff

September 10th 2022

Neurology News Network for the week ending September 10, 2022. [WATCH TIME: 4 minutes]

Weekly Recap

Remternetug Significantly Reduces Amyloid Plaque, Phase 3 INTUNE Study Accelerated, Pitolisant Approved for Pediatric Narcolepsy by EMA

Lecanemab Adds Quality-Adjusted Life Years, FDA to Hold AdComm Meeting Over NurOwn, SYMBYX Neuro Improves PD Symptoms

Efgartigimod Effective Across Subgroups, FDA to Hold AdComm Meeting on SRP-9001, Reboxetine Demonstrates Positive Effect on Obstructive Sleep Apnea

Cognitive and Functional Differences in Parkinson, FDA Lifts Hold on IkT-148009, Solanezumab Shows No Impact on Cognitive Decline

Efgartigimod Improves HR-Related Quality of Life, Traditional Approval for Lecanemab Pending, Satrlizumab Benefits NMOSD After Switching

Gene Therapy ST-920 Shows Benefit in Fabry, Intermittent Calorie Restriction in Multiple Sclerosis, High Economic Burden Identified in NMOSD

Sodium Oxybate Alters Sleep Structure, FDA Approves Deutetrabenazine, Associations of Stroke Decreased With Age

CNM-Au8 Impacts Neuronal Structural Integrity, Mobile Stroke Units and Direct Transfer to Angiography, Cognitive Impairments Higher in RBD Before Parkinson Disease

PHOENIX Study Meets Enrollment, Atogepant and Ubrogepant Safe, ABATE Trial Highlights Targeted Response of Alzheimer Vaccine

New Diagnostic Criteria Established for MOGAD, FDA Approves Proclaim XR SCS System, Clinical Hold on IKT-148009 Lifted

Evoke SCS System Shows Positive 36-Month Results, FDA Lifts Hold on FORTIS, Complete Response Letter Issued for Donanemab

COVID-19 Vaccine and Potential Stroke Concern, Associations Between AEDs and Incident Parkinson, FDA Accepts sBLA for DaxibolinumtoxinA

24-Hour Levodopa Solution Improves ON Time, Eisai Submits sBLA for Traditional Approval of Lecanemab, Rare Case of Seronegative NMOSD Identified

FDA Approves Essential Tremor Treatment, Alzheimer's Association Files Request to CMS, Duchenne Therapy ENTR-601-44 Placed on Hold

WVE-N531's Impact on Exon Skipping, PROs Improved With Early DMT Initiation, Carbon Dioxide Improves Insomnia Sleep

Genetic Links to PML Identified, MARINA Trial Findings Announced, Educational Videos Improve CPAP Adherence

Communication Critical for Dravet Syndrome, DNL343 to Enter HEALEY ALS Trial, Combination of Seizures and Dementia Leads to Worse Outcomes

Donanemab Outperforms Aducanumab in Amyloid Clearance, FDA Grants Priority Review to SRP-9001, Atogepant Improves PROs

Aquatic Therapy Improves MS Fatigue, MS Disease Pathology Not Defined by Courses, Rituximab Shows Positive Effect in Myasthenia Gravis

Positive Results of STK-001 in Dravet, Zavegepant Meets Primary End Points, FDA Accepts NDA of Zilucoplan for Myasthenia Gravis

FDA Rejects BLA for NurOwn, Simvastatin Futile as DMT for Parkinson, Music Potentially Improves Insomnia Symptoms

Poor Sleep Associated With Cannabis and Alcohol Use, Dietary Approaches in MS, Noninvasive Brain Stimulation Effective in Alzheimer

Apitegromab Improves Quality of Life in SMA, ARB Therapy Leads to Lowered Epilepsy Risk, Donanemab Reduces Alzheimer-Related Plasma Biomarkers

Positive Interim Report on Fosgonimeton, Lower ASPECTS Scores Impact Efficacy of EVT, FDA Extends Review of Tofersen

Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD

Ublituximab Outperforms Teriflunomide on ARRs, CNM-Au8 Fails HEALEY ALS Trial, Benefits of Aerobic Exercise in Multiple Sclerosis

Verdiperstat Fails ALS Study, Lecanemab Shines in Latest Phase 3 Findings, Ofatumumab Continues Superiority Over Teriflunomide

Rituximab as Initial gMG Treatment, WVE-003 Proves Positive in HD, and Incidence of Guillian-Barré After COVID-19 Vaccination

Abnormal Vascular Hemodynamics Linked With Tau, Constant Therapy Shows Feasibility in Alzheimer Disease, LIFT-AD Study Amended

New Study on COVID-19 Vaccinations in MS, FDA Lifts Hold on SRP-5051, Implantable Loop Recorder and Atrial Fibrillation

Trending on NeurologyLive

Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits

Evolving Responsibilities of Vice Chairs in Neurology Leadership: Mud Alvi, MD

Current Challenges and New Opportunities Ahead for Women in Neurology

Managing Dyskinesia Through Continuous Infusion Therapy